JPMorgan analyst Casey Woodring raised the firm’s price target on Illumina (ILMN) to $130 from $105 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $110 from $100 at Barclays
- Illumina, MyOme announces collaboration, investment by Illumina into MyOme
- Illumina Completes $500M Notes Offering for Expansion
- Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS
- Illumina Announces $500M Notes Issuance Agreement